TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22933501

Group type: EXPERIMENTAL
Intervention: HIV-positive patients undergoing clean surgery
Number of subjects: 609

Group type: COMPARATOR
Intervention: HIV-negative patients undergoing clean surgery
Number of subjects: 609

Group type: EXPERIMENTAL
Intervention: HIV-positive patients with open fractures or contamination
Number of subjects: 609

Group type: COMPARATOR
Intervention: HIV-negative patients with open fractures or contamination
Number of subjects: 609

Group type: EXPERIMENTAL
Intervention: HIV-positive patients
Number of subjects: 609

Group type: EXPERIMENTAL
Intervention: HIV-positive patients with previous contamination
Number of subjects: 609
Study: 19243306

Group type: EXPERIMENTAL
Intervention: OXN PR (60-80 mg/day)
Number of subjects: 265

Group type: COMPARATOR
Intervention: OXY PR alone (60-80 mg/day)
Number of subjects: 265
Study: 18724187

Group type: EXPERIMENTAL
Intervention: Eban Health Promotion Intervention
Number of subjects: 0
Study: 16331792

Group type: EXPERIMENTAL
Intervention: Synovial tissue analysis in treatment strategies for rheumatoid arthritis
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not specified
Number of subjects: 0
Study: 11853235

Group type: EXPERIMENTAL
Intervention: Super‐EBA (EBA) root-end fillings
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Pro Root MTA (MTA) root-end fillings
Number of subjects: 24

Group type: COMPARATOR
Intervention: Microcracking
Number of subjects: 24
Study: 10443984

Group type: EXPERIMENTAL
Intervention: Naloxone hydrochloride (0 and 125 microg/kg)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Cosyntropin (0, 0.25 microg, and 250 microg)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Cortisol monitoring over a 24‐hr interval
Number of subjects: 78
Study: 7778636

Group type: EXPERIMENTAL
Intervention: Intravaginal misoprostol (50 microgram tablets every 3 hours for a maximum of six doses)
Number of subjects: 135

Group type: COMPARATOR
Intervention: Intracervical dinoprostone (0.5 mg every 6 hours for a maximum of three doses)
Number of subjects: 135

Group type: COMPARATOR
Intervention: Intracervical dinoprostone
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Intravaginal misoprostol
Number of subjects: 135
Study: 2138488

Group type: EXPERIMENTAL
Intervention: Spinal anaesthesia using a 29-gauge spinal needle
Number of subjects: 100

Group type: COMPARATOR
Intervention: General anaesthesia
Number of subjects: 100
Study: 7189333

Group type: COMPARATOR
Intervention: Morphine sulfate (2 mg/kg)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Lidocaine (21 mg/kg)
Number of subjects: 40
Study: 30528459

Group type: EXPERIMENTAL
Intervention: Intraneural injection (1ml solution)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Perineural injection (1ml solution)
Number of subjects: 60
Study: 28938956

Group type: EXPERIMENTAL
Intervention: Ticagrelor 180 mg followed by 90 mg twice daily
Number of subjects: 140

Group type: COMPARATOR
Intervention: Clopidogrel 300 mg followed by 75 mg daily
Number of subjects: 140
Study: 24117412

Group type: EXPERIMENTAL
Intervention: Reduced-fluence photodynamic therapy (RDPDT) with Verteporfin (25 J/cm²) followed by intravitreal bevacizumab 1.25 mg
Number of subjects: 95

Group type: COMPARATOR
Intervention: Intravitreal bevacizumab alone
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Reduced-fluence photodynamic therapy (RDPDT) with Verteporfin followed by intravitreal bevacizumab
Number of subjects: 95
Study: 22324456

Group type: EXPERIMENTAL
Intervention: BCP (Straumann BoneCeramic)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: ABB (Geistlich Bio‐Oss)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: AB (Autologous Bone)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: MCBA (Zimmer Puros)
Number of subjects: 30
Study: 21495900

Group type: EXPERIMENTAL
Intervention: 1 g E. officinalis powder per day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 2 g E. officinalis powder per day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 3 g E. officinalis powder per day
Number of subjects: 0
Study: 19535707

Group type: EXPERIMENTAL
Intervention: Epidural morphine administered 30 min before 2-chloroprocaine anesthesia (n = 29)
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Epidural morphine administered after 2-chloroprocaine anesthesia (n = 30)
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Epidural morphine administered after lidocaine anesthesia (n = 28)
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Pain scores in the postanesthesia care unit
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Pain scores on admission to the postpartum unit
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Supplemental morphine equivalents administered in the first 48 h
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Opioid-related side effects
Number of subjects: 87
Study: 17438515

Group type: EXPERIMENTAL
Intervention: Estrogen-containing oral contraceptives
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Estrogen treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hormone therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Delayed hormone therapy
Number of subjects: 0
Study: 15110204

Group type: EXPERIMENTAL
Intervention: Statin therapy administered to 134 patients (12%)
Number of subjects: 1153

Group type: EXPERIMENTAL
Intervention: Statin therapy after propensity score analyses
Number of subjects: 1153
Study: 11180010

Group type: EXPERIMENTAL
Intervention: Recombinant interleukin-10 administered subcutaneously over 6 weeks
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Recombinant interleukin-10
Number of subjects: 14
Study: 9274063

Group type: EXPERIMENTAL
Intervention: Iris 3000 foam mattress overlays (n = 20)
Number of subjects: 40

Group type: COMPARATOR
Intervention: MAXIFLOAT foam mattress replacements (n = 20)
Number of subjects: 40
Study: 8092234

Group type: EXPERIMENTAL
Intervention: Long-term down-regulation for 2 to 7 months followed by human menopausal gonadotropin and human chorionic gonadotropin
Number of subjects: 84

Group type: COMPARATOR
Intervention: Control group with short protocol using gonadotropin-releasing hormone agonist followed by human menopausal gonadotropin and human chorionic gonadotropin
Number of subjects: 84
Study: 3277827

Group type: EXPERIMENTAL
Intervention: BAY m 1099
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: BAY o 1248
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: BAY m 1099 and BAY o 1248
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 31574262

Group type: EXPERIMENTAL
Intervention: QuadraLite face mask
Number of subjects: 48

Group type: COMPARATOR
Intervention: Air cushion face mask
Number of subjects: 48
Study: 28445632

Group type: EXPERIMENTAL
Intervention: Olanzapine plus sertraline
Number of subjects: 258

Group type: COMPARATOR
Intervention: Olanzapine plus placebo
Number of subjects: 258
Study: 25901426

Group type: EXPERIMENTAL
Intervention: Involved-field radiotherapy
Number of subjects: 602

Group type: COMPARATOR
Intervention: No further therapy
Number of subjects: 602
Study: 24190112

Group type: EXPERIMENTAL
Intervention: Paclitaxel (80 mg/m² on days 1, 8, and 15, every 4 weeks)
Number of subjects: 219

Group type: COMPARATOR
Intervention: Irinotecan (150 mg/m² on days 1 and 15, every 4 weeks)
Number of subjects: 219

Group type: EXPERIMENTAL
Intervention: Paclitaxel
Number of subjects: 219

Group type: COMPARATOR
Intervention: Irinotecan
Number of subjects: 219
Study: 21944095

Group type: EXPERIMENTAL
Intervention: Watchful waiting
Number of subjects: 1230

Group type: EXPERIMENTAL
Intervention: Delayed treatment after initially waiting
Number of subjects: 1230
Study: 18308781

Group type: EXPERIMENTAL
Intervention: Galantamine
Number of subjects: 285
Study: 16848646

Group type: EXPERIMENTAL
Intervention: Sertraline (50-200 mg/day)
Number of subjects: 326

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 326
Study: 12707158

Group type: EXPERIMENTAL
Intervention: Infusion of lactated Ringer's solution 40 mL/kg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Background infusion of lactated Ringer's solution 5 mL/kg
Number of subjects: 12
Study: 10865416

Group type: EXPERIMENTAL
Intervention: Cigarette smoking (smokers)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Non-smoking (non-smokers)
Number of subjects: 40
Study: 9181530

Group type: EXPERIMENTAL
Intervention: Leucocyte (Le) IFN-alpha
Number of subjects: 69

Group type: COMPARATOR
Intervention: Control (second course of the same IFN-alpha)
Number of subjects: 69
Study: 1302572

Group type: EXPERIMENTAL
Intervention: MammaCare training technique
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Concentric circle training technique
Number of subjects: 101

Group type: COMPARATOR
Intervention: Baseline assessment
Number of subjects: 101
Study: 4016830

Group type: EXPERIMENTAL
Intervention: Mezlocillin (5-gm dose administered intravenously 30 minutes before surgery)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (administered intravenously 30 minutes before surgery)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mezlocillin
Number of subjects: 0
Study: 29766275

Group type: EXPERIMENTAL
Intervention: Cough Reflex Testing (CRT)
Number of subjects: 488

Group type: COMPARATOR
Intervention: Standard Care (bedside assessment)
Number of subjects: 488
Study: 27686346

Group type: EXPERIMENTAL
Intervention: Intravenous iron
Number of subjects: 140

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 140
Study: 24239600

Group type: EXPERIMENTAL
Intervention: Hyangsa-Pyeongwi san (HPS) 9.68g at once, three times daily for 4 weeks
Number of subjects: 170

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 170
Study: 21869730

Group type: EXPERIMENTAL
Intervention: enalapril FA tablet (10 : 0.4 mg, low‐FA group)
Number of subjects: 480

Group type: EXPERIMENTAL
Intervention: enalapril FA tablet (10 : 0.8 mg, high‐FA group)
Number of subjects: 480

Group type: COMPARATOR
Intervention: enalapril only (10 mg, control group)
Number of subjects: 480
Study: 20569064

Group type: EXPERIMENTAL
Intervention: Antiretroviral therapy during tuberculosis therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Tuberculosis therapy alone
Number of subjects: 0
Study: 18280582

Group type: EXPERIMENTAL
Intervention: Inpatient treatment for schizophrenia or schizophreniform disorders
Number of subjects: 200
Study: 16172596

Group type: EXPERIMENTAL
Intervention: Almond milk (Group A, n=26)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Soy-based formula (Group B, n=13)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Protein hydrolysate-based formula (n=13)
Number of subjects: 52
Study: 14653235

Group type: EXPERIMENTAL
Intervention: Bougienage and omeprazole (20 mg/day for 12 months)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Bougienage and ranitidine (300 mg/day for 12 months)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Only bougienage
Number of subjects: 100
Study: 11130802

Group type: EXPERIMENTAL
Intervention: Telephone counseling
Number of subjects: 1443

Group type: EXPERIMENTAL
Intervention: Mail counseling
Number of subjects: 1443

Group type: COMPARATOR
Intervention: Control
Number of subjects: 1443
Study: 9020535

Group type: EXPERIMENTAL
Intervention: Multitest CMI
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: CD4/CD8 ratio
Number of subjects: 20
Study: 1412119

Group type: EXPERIMENTAL
Intervention: Budesonide (1.6 mg inhaled per day for three weeks)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Prednisone (40 mg oral per day for eight days)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Salbutamol
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Ipratropium
Number of subjects: 10
Study: 6443771

Group type: EXPERIMENTAL
Intervention: Cefsulodin
Number of subjects: 29

Group type: COMPARATOR
Intervention: Tobramycin
Number of subjects: 29

Group type: COMPARATOR
Intervention: Ticarcillin
Number of subjects: 29
Study: 30988711

Group type: EXPERIMENTAL
Intervention: BIOF2 treatment (intra-articular BIOF2 application at 0, 1 and 2 months)
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: BIOF2 treatment (intra-articular BIOF2 application at 0, 1 and 2 months) excluding patients with class 2 obesity or malalignment
Number of subjects: 212

Group type: COMPARATOR
Intervention: Usual medical care (paracetamol/NSAIDs and general care provided by the family physician)
Number of subjects: 212
Study: 30323196

Group type: EXPERIMENTAL
Intervention: 5 validated lncRNAs
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Training set
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Validation set
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Co-expression network
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: KEGG pathway enrichment analysis
Number of subjects: 500
Study: 27327233

Group type: EXPERIMENTAL
Intervention: Experimental protocol (15 s CPR during and after charging of the AED, immediate CPR resumption after defibrillation)
Number of subjects: 456

Group type: COMPARATOR
Intervention: Control protocol (post-shock analysis and pulse check as per Guidelines 2000)
Number of subjects: 456

Group type: EXPERIMENTAL
Intervention: Experimental protocol
Number of subjects: 456

Group type: COMPARATOR
Intervention: Control protocol
Number of subjects: 456
Study: 23336207

Group type: EXPERIMENTAL
Intervention: Intralesional PPD antigen
Number of subjects: 40

Group type: COMPARATOR
Intervention: Intralesional saline (control)
Number of subjects: 40
Study: 22406697

Group type: EXPERIMENTAL
Intervention: Dehydration trial (2.5% body weight loss)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Euhydration trial (rested state)
Number of subjects: 12
Study: 20195744

Group type: EXPERIMENTAL
Intervention: Ovarian function suppression plus 5 years of tamoxifen with anthracycline-based chemotherapy
Number of subjects: 174

Group type: COMPARATOR
Intervention: Ovarian function suppression plus 5 years of tamoxifen without chemotherapy (endocrine therapy alone)
Number of subjects: 174

Group type: COMPARATOR
Intervention: Adjuvant! estimate for endocrine therapy alone
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: Adjuvant! estimate for chemoendocrine therapy
Number of subjects: 174
Study: 17919634

Group type: EXPERIMENTAL
Intervention: Gut-directed hypnotherapy (HT) consisting of 6 sessions over a 3-month period.
Number of subjects: 53

Group type: COMPARATOR
Intervention: Standard medical therapy (SMT) with 6 sessions of supportive therapy.
Number of subjects: 53
Study: 11674922

Group type: EXPERIMENTAL
Intervention: Active treatment (sublingual immunotherapy with a biologically standardised extract of three pollens)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Active treatment (sublingual immunotherapy) during the second year
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (treated only with drugs)
Number of subjects: 30
Study: 9272652

Group type: EXPERIMENTAL
Intervention: Falling blood glucose levels during cognitive tasks
Number of subjects: 0
Study: 8048681

Group type: EXPERIMENTAL
Intervention: Sexual education and medical consultations for adolescents with emphasis on contraception
Number of subjects: 1010

Group type: EXPERIMENTAL
Intervention: Induced abortions as a pregnancy outcome
Number of subjects: 1010

Group type: EXPERIMENTAL
Intervention: Low level of effective contraceptive use
Number of subjects: 1010
Study: 2882607

Group type: EXPERIMENTAL
Intervention: Naproxen sodium (550 mg)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Propoxyphene napsylate with acetaminophen (PN/A, 100 mg with 650 mg)
Number of subjects: 52
Study: 31679865

Group type: EXPERIMENTAL
Intervention: MF59®‐adjuvanted trivalent influenza vaccine (aTIV; Fluad®)
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: Highest dosage of antigen in combination with the highest dosage of adjuvant
Number of subjects: 196

Group type: COMPARATOR
Intervention: Modified aTIV formulations
Number of subjects: 196
Study: 28940259

Group type: EXPERIMENTAL
Intervention: Guselkumab
Number of subjects: 1829

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1829

Group type: COMPARATOR
Intervention: Adalimumab
Number of subjects: 1829
Study: 26763271

Group type: EXPERIMENTAL
Intervention: Extracorporeal shock wave therapy (1000 impulses and 2.1 bar)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Corticosteroid injection
Number of subjects: 40
Study: 24074486

Group type: EXPERIMENTAL
Intervention: Aspirin + Clopidogrel dual therapy
Number of subjects: 546

Group type: EXPERIMENTAL
Intervention: Clopidogrel
Number of subjects: 546

Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 546

Group type: COMPARATOR
Intervention: Control group (healthy individuals)
Number of subjects: 546

Group type: EXPERIMENTAL
Intervention: Study group (patients on anti-platelet therapy)
Number of subjects: 546

Group type: EXPERIMENTAL
Intervention: Dual therapy
Number of subjects: 546
Study: 23159587

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 20649945

Group type: EXPERIMENTAL
Intervention: Topically applied pure lavender oil (1 ml of 30% high strength essential lavender oil)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo oil (jojoba oil only)
Number of subjects: 0
Study: 18207205

Group type: EXPERIMENTAL
Intervention: Astringent solution (5 g L(‐1) tannic acid in distilled water)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Distilled drinking water
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Sweet solution (40 g L(‐1) sugar in mango tea with no tannins)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Mouth dried with air for 35 s
Number of subjects: 12

Group type: COMPARATOR
Intervention: Mouth not dried (waiting for equal period of time)
Number of subjects: 12
Study: 16415706

Group type: EXPERIMENTAL
Intervention: Reduced-dose group
Number of subjects: 34

Group type: COMPARATOR
Intervention: Fixed-dose group
Number of subjects: 34
Study: 12406840

Group type: EXPERIMENTAL
Intervention: Autotitrating CPAP
Number of subjects: 44
Study: 11058797

Group type: EXPERIMENTAL
Intervention: Delayed sleep phase syndrome (DSPS) patients
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Non‐24‐h sleep‐wake syndrome (non‐24) patients
Number of subjects: 28

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 28
Study: 8840101

Group type: EXPERIMENTAL
Intervention: Diet
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Sulphonylurea
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Insulin therapy
Number of subjects: 132
Study: 1632166

Group type: EXPERIMENTAL
Intervention: Intrathecal morphine (0.3 mg) + bupivacaine (20 mg)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Postoperative naloxone infusion (1 microgram/kg/h over 12 h, 0.25 micrograms/kg/h over the next 12 h) + bupivacaine (20 mg) + morphine (0.3 mg)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Bupivacaine (20 mg)
Number of subjects: 30
Study: 31539267

Group type: EXPERIMENTAL
Intervention: Machine-learning models for objective response (OR)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Machine-learning models for progression-free survival (PFS)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Machine-learning models for overall survival (OS)
Number of subjects: 17
Study: 28215413

Group type: EXPERIMENTAL
Intervention: SBP/RAP ratio <11
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: SBP/RAP ratio <8
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: SBP/RAP
Number of subjects: 195

Group type: COMPARATOR
Intervention: RAP
Number of subjects: 195

Group type: COMPARATOR
Intervention: SBP
Number of subjects: 195
Study: 26260354

Group type: EXPERIMENTAL
Intervention: S. boulardii 250 mg
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: S. boulardii 250 mg plus BS 524 mg
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: BS 524 mg
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 25551571

Group type: EXPERIMENTAL
Intervention: peginterferon beta-1a every 2 weeks
Number of subjects: 1512

Group type: COMPARATOR
Intervention: peginterferon beta-1a every 4 weeks
Number of subjects: 1512

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 1512
Study: 23270444

Group type: EXPERIMENTAL
Intervention: normoxia + vitamin C
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: hypoxia + vitamin C
Number of subjects: 24

Group type: COMPARATOR
Intervention: normoxia control
Number of subjects: 24

Group type: COMPARATOR
Intervention: hypoxia control
Number of subjects: 24
Study: 19362455

Group type: EXPERIMENTAL
Intervention: Bitter melon (55 ml/24h)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Rosiglitazone (4 mg/24h)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 25
Study: 18500525

Group type: EXPERIMENTAL
Intervention: 150 ml of oral contrast agent
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: 300 ml of oral contrast agent
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: 450 ml of oral contrast agent
Number of subjects: 6
Study: 15509637

Group type: EXPERIMENTAL
Intervention: Testosterone enanthate (TE, 100 mg im weekly) + levonorgestrel (LNG, 125 microg orally daily)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Testosterone enanthate (TE, 100 mg im weekly) + levonorgestrel (LNG, 125 microg orally daily) + dutasteride (0.5 mg orally daily)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Testosterone enanthate (TE, 100 mg im weekly) + acyline (300 microg/kg sc every 2 wk)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Testosterone enanthate (TE, 100 mg im weekly) + levonorgestrel (LNG, 125 microg orally daily) + acyline (300 microg/kg sc every 2 wk)
Number of subjects: 22
Study: 12523585

Group type: EXPERIMENTAL
Intervention: O 20 mg, clarithromycin (C) 250 mg, metronidazole (M) 500 mg (O.C.M)
Number of subjects: 426

Group type: EXPERIMENTAL
Intervention: RBC 400 mg, clarithromycin (C) 250 mg, metronidazole (M) 500 mg (RBC.C.M)
Number of subjects: 426

Group type: EXPERIMENTAL
Intervention: RBC 400 mg, tetracycline (T) 1000 mg, metronidazole (M) 500 mg (RBC.T.M)
Number of subjects: 426
Study: 10375099

Group type: EXPERIMENTAL
Intervention: Chronomodulated 5‐FU (700 mg/m2/day), LV (300 mg/m2/day), and 1‐OHP (25 mg/m2/day) for 4 days every 14 days.
Number of subjects: 90
Study: 8600888

Group type: EXPERIMENTAL
Intervention: Silicone Study Classification System
Number of subjects: 287

Group type: EXPERIMENTAL
Intervention: Retina Society Classification System
Number of subjects: 287
Study: 1767242

Group type: EXPERIMENTAL
Intervention: Aniracetam (1500 mg/day per os)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 6412896

Group type: EXPERIMENTAL
Intervention: terbutaline sulphate
Number of subjects: 30

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 30